Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics (NASDAQ: CRSP ) stock rose 5% on news the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It's the first authorization in the world for the CRISPR gene-editing technology.

CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy

Crispr Therapeutics (NASDAQ: CRSP) stock price will be in the spotlight on Thursday after the company made a major breakthrough in the UK. The shares surged to a multi-month high of $60 in the pre-market session.

Crispr Therapeutics (CRSP) stock price is on the cusp of a 25% pop

CRISPR Therapeutics shares have advanced this year, but they're still far from their peak. The company is heading for its biggest moment ever: potential product approval.

Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.

Vertex Pharmaceuticals

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY has been authorized.

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

ChargePoint Holdings

Medtronic

Rocket Lab USA

SharkNinja Inc

Tilray Brands

One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor interest before falling back to Earth.

Invest in the Future With These 7 Forever Stocks

Arcutis Biotherapeutics

2Seventy Bio

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

3 Biotech Stocks With Key Catalysts Coming in December

Amazon

Growth stocks could lead this latest market rally -- and may deliver growth to your portfolio over time. Amazon and CRISPR Therapeutics are well positioned to benefit from the next bull market.

2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher

Incyte

Shockwave Medical

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too risky for me.

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.

1 No-Brainer Stock to Buy and Hold for 10 Years

Editas Medicine

Intellia Therapeutics

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

ACADIA Pharma

Exelixis

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.

3 Biotech Stocks With the Strongest Clinical Pipelines

CRISPR Therapeutics could soon have an approved product in its portfolio. The stock's modest valuation suggests there could be significant upside.

Why CRISPR Therapeutics Stock Could Be About to Take Off

There's nothing like a convincing quarterly earnings beat. The gene-editing specialist's net loss was far narrower than expected.

Why CRISPR Therapeutics Stock Crushed the Market Today

CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.

CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected

From a technical perspective, CRISPR Therapeutics AG (CRSP) is looking like an interesting pick, as it just reached a key level of support. CRSP recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving Average

-Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD-

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose-

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

Beam Therapeutics

Biotech stocks have been under extreme pressure over the prior 24 months. This industry-wide move lower may have created a handful of once-in-a-lifetime opportunities for investors.

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage for the first CRISPR/Cas9-based therapy to hit the market next year.

Why CRISPR Therapeutics Stock Charged Northward This Week

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA

Johnson & Johnson

One of these players is approaching a big milestone: potential product approval. The other two companies recently made moves to transform their businesses, and this may spur a new chapter of growth.

3 Healthcare Stocks to Buy Hand Over Fist in November

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, suggesting a short-term bullish trend.

CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 108.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High?

CRISPR Therapeutics' first gene-editing candidate is moving closer to the finish line. An FDA advisory meeting this week set a positive tone ahead of a big regulatory decision.

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for CRISPR Therapeutics Stock (CRSP)